BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 28648755)

  • 1. High Expression of Long Noncoding RNA MALAT1 Indicates a Poor Prognosis and Promotes Clinical Progression and Metastasis in Bladder Cancer.
    Li C; Cui Y; Liu LF; Ren WB; Li QQ; Zhou X; Li YL; Li Y; Bai XY; Zu XB
    Clin Genitourin Cancer; 2017 Oct; 15(5):570-576. PubMed ID: 28648755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of long noncoding RNA NORAD indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer.
    Li Q; Li C; Chen J; Liu P; Cui Y; Zhou X; Li H; Zu X
    Urol Oncol; 2018 Jun; 36(6):310.e15-310.e22. PubMed ID: 29605462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder.
    Han Y; Liu Y; Nie L; Gui Y; Cai Z
    Urology; 2013 Jan; 81(1):209.e1-7. PubMed ID: 23153939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma.
    Zhang HM; Yang FQ; Chen SJ; Che J; Zheng JH
    Tumour Biol; 2015 Apr; 36(4):2947-55. PubMed ID: 25480417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression.
    Zhang Y; Chen Z; Li MJ; Guo HY; Jing NC
    Biomed Pharmacother; 2017 Jan; 85():264-271. PubMed ID: 27887846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
    Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Loo LWM; Jia W; Obata Y; Yu H
    Breast Cancer Res Treat; 2018 Sep; 171(2):261-271. PubMed ID: 29845475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-β-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12.
    Fan Y; Shen B; Tan M; Mu X; Qin Y; Zhang F; Liu Y
    Clin Cancer Res; 2014 Mar; 20(6):1531-41. PubMed ID: 24449823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased MALAT1 expression predicts poor prognosis in esophageal cancer patients.
    Huang C; Yu Z; Yang H; Lin Y
    Biomed Pharmacother; 2016 Oct; 83():8-13. PubMed ID: 27470544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer.
    Pang EJ; Yang R; Fu XB; Liu YF
    Tumour Biol; 2015 Apr; 36(4):2403-7. PubMed ID: 25481511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer.
    Zhao XL; Zhao ZH; Xu WC; Hou JQ; Du XY
    Int J Clin Exp Pathol; 2015; 8(2):1954-60. PubMed ID: 25973088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.
    Iliev R; Kleinova R; Juracek J; Dolezel J; Ozanova Z; Fedorko M; Pacik D; Svoboda M; Stanik M; Slaby O
    Tumour Biol; 2016 Oct; 37(10):13385-13390. PubMed ID: 27460088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 inhibits the proliferation and migration of bladder cancer cells by modulating the microRNA-34a/cyclin D1 axis.
    Liu Y; Gao S; Du Q; Zhao Q
    Int J Mol Med; 2019 Jan; 43(1):547-556. PubMed ID: 30387807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations of Foxo3 and Foxo4 expressions with clinicopathological features and prognosis of bladder cancer.
    Wang Y; Kang XL; Zeng FC; Xu CJ; Zhou JQ; Luo DN
    Pathol Res Pract; 2017 Jul; 213(7):766-772. PubMed ID: 28554751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of increased MALAT1 expression with pathological features and prognosis in cancer patients: a meta-analysis.
    Shi XS; Li J; Yang RH; Zhao GR; Zhou HP; Zeng WX; Zhou M
    Genet Mol Res; 2015 Dec; 14(4):18808-19. PubMed ID: 26782531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of long non-coding RNA MALAT1 for predicting the recurrence and metastasis of gallbladder cancer and its effect on cell proliferation, migration, invasion, and apoptosis.
    Sun KK; Hu PP; Xu F
    J Cell Biochem; 2018 Apr; 119(4):3099-3110. PubMed ID: 29058818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA MALAT1 is an independent prognostic factor of osteosarcoma.
    Gao KT; Lian D
    Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3561-5. PubMed ID: 27649655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. lncRNA Up-Regulated in Nonmuscle Invasive Bladder Cancer Facilitates Tumor Growth and Acts as a Negative Prognostic Factor of Recurrence.
    Zhang S; Zhong G; He W; Yu H; Huang J; Lin T
    J Urol; 2016 Oct; 196(4):1270-8. PubMed ID: 27267320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of long non‑coding RNA n346372 in bladder cancer tissues is associated with a poor prognosis.
    Liu A; Zhang Z; Xu W; Qin S; Hua M; Zeng S; Xu C
    Mol Med Rep; 2018 Dec; 18(6):5437-5444. PubMed ID: 30365104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MALAT1 promoted invasiveness of gastric adenocarcinoma.
    Lee NK; Lee JH; Ivan C; Ling H; Zhang X; Park CH; Calin GA; Lee SK
    BMC Cancer; 2017 Jan; 17(1):46. PubMed ID: 28077118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA GHET1 promotes the development of bladder cancer.
    Li LJ; Zhu JL; Bao WS; Chen DK; Huang WW; Weng ZL
    Int J Clin Exp Pathol; 2014; 7(10):7196-205. PubMed ID: 25400817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.